Creating Equitable and Inclusive Clinical Trials for Multiple Myeloma

Clin Lymphoma Myeloma Leuk. 2024 Jan;24(1):32-39. doi: 10.1016/j.clml.2023.09.004. Epub 2023 Sep 15.

Abstract

Black and Latino/Hispanic populations are disproportionately impacted by multiple myeloma (MM) in the United States and are underrepresented in many clinical trials. The Multiple Myeloma Research Foundation sponsored a 1-day workshop of 46 experts spanning the ecosystem of MM research and care, including government, academia, nonprofits, pharma/biotech, community partners, and retail pharmacy. Specific, tangible steps to overcome the well-documented barriers to improving the diversity and inclusivity of clinical trials were discussed, including broadening inclusion/exclusion criteria, reducing the financial and other burdens of trial participants, selecting diverse study sites, including implicit bias training, and taking steps to empower patients.

Keywords: Clinical trial; Diversity; Equity; Inclusivity; Multiple myeloma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Black or African American
  • Clinical Trials as Topic*
  • Hispanic or Latino
  • Humans
  • Multiple Myeloma* / therapy
  • Patient Selection